By Tom Hallam, Ph.D., MBA For small pharma companies navigating the road to US market approval, the right nonclinical regulatory strategy, built with expert consulting and scientific guidance, can mean the difference between ef...
When preparing for a meeting with the FDA, most Sponsors focus on regulatory affairs, clinical leads, or medical officers. However, one role that is becoming increasingly central and often overlooked is the statistician. Whethe...
When developing a new drug, early engagement with FDA through a Pre-Investigational New Drug (Pre-IND) meeting can set the stage for a smoother regulatory process. This meeting is essential to avoid clinical holds and prevent c...
Preparing for a Pre-Biologics License Application (Pre-BLA) meeting with FDA is a pivotal step in the regulatory journey for sponsors seeking to bring a biologic product to market. This meeting provides an invaluable opportunit...
For life sciences companies navigating the FDA regulatory landscape, Type A meetings are generally considered informative meetings focused on resolving issues. They primarily apply to the drug and biologic development process u...
Effective communication with FDA through various FDA meetings is essential for a smooth and efficient drug development process. While Type A, B, and C meetings have long been established as key regulatory meeting types, FDA int...
When developing a new drug or biologic, timely and strategic engagement with FDA can be the key to a smoother regulatory pathway. While Type A and Type B meetings are often tied to critical milestones, Type C meetings serve as ...
A Type B meeting (also called a Milestone Meeting or an Entitled Meeting) is a formal meeting between the sponsor and FDA to discuss product development and next steps. These meetings are crucial to keep product development mov...
Communication with FDA when developing innovative pharmaceuticals and biologics is a key driver of success. Early and ongoing engagement with FDA can streamline development, reduce risks, and ensure that a company’s regul...
gET sOCIAL